CATALYST PHARMACEUTICALS, INC. 8-K

What Happened

• Catalyst Pharmaceuticals, Inc. announced that at a special meeting held July 8, 2026 shareholders approved the Merger Agreement dated May 6, 2026 under which Angelini Cielo Inc. (a subsidiary of Angelini Pharma S.p.A.) will merge into Catalyst, with Catalyst becoming a wholly owned subsidiary of Angelini Pharma. The Merger Proposal received 97,340,180 votes in favor, 1,143,815 votes against and 242,616 abstentions. Approval of the Merger Proposal satisfies one of the closing conditions under the Merger Agreement.
• In connection with the anticipated closing, each current director (Patrick J. McEnany; Richard J. Daly; Daniel J. Curran, M.D.; Donald A. Denkhaus; Molly Harper; Tamar Thompson; and David S. Tierney, M.D.) has indicated an intention to resign from the board and any committee thereof, conditioned on and effective at the Merger’s effective time.

Key Details

• Record date and meeting turnout: 122,417,458 shares outstanding as of the June 3, 2026 record date; 98,726,611 shares (≈80.6%) were present in person or by proxy at the July 8 special meeting.
• Merger vote: For 97,340,180; Against 1,143,815; Abstentions 242,616.
• Advisory compensation vote (non-binding) failed: For 30,504,686; Against 67,486,884; Abstentions 735,041. This advisory vote is not a condition to closing.
• The Merger Agreement was dated May 6, 2026; shareholder approval removes a key condition but other closing conditions (including regulatory approvals) remain.

Why It Matters

• For investors, shareholder approval is a major step toward the acquisition by Angelini Pharma and signals likely change of ownership and control pending remaining closing conditions. Director resignations upon closing indicate imminent board turnover and governance changes.
• The failed non-binding advisory vote on merger-related executive compensation does not prevent closing but signals shareholder dissatisfaction with certain pay matters, which may influence post-close integration and governance disclosures.
• The transaction still depends on other conditions (e.g., regulatory clearances and other closing requirements) as described in the Definitive Proxy Statement; investors should monitor subsequent filings for closing updates and any material developments.